Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | MYOC | Q99972 | 1/20 | 0.55 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.54 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.52 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28561063 | 0.88 | SRD5A2 (0.90) | MEN1KMT2AKDM4ESRD5A2TDP1 | |
| SCHEMBL6623045 | 0.88 | SRD5A2 (0.90) | MEN1KMT2AKDM4ESRD5A2TDP1 | |
| SCHEMBL1025785 | 0.87 | MEN1 (0.75) | MEN1KMT2AKDM4ESRD5A2TDP1 | |
| SCHEMBL177838 | 0.86 | KDM4E (1.00) | MEN1KMT2AKDM4ESRD5A2TDP1 | |
| SCHEMBL311582 | 0.86 | KMT2A (0.73) | MEN1KMT2AKDM4ESRD5A2RAB9A | |
| SCHEMBL9068673 | 0.85 | MEN1 (0.74) | MEN1KMT2AKDM4ESRD5A2FFAR1 | |
| SCHEMBL28565012 | 0.83 | SRD5A2 (0.82) | MEN1KMT2AKDM4ESRD5A2TDP1 | |
| SCHEMBL6014080 | 0.83 | MEN1 (0.71) | MEN1KMT2AKDM4ESRD5A2TDP1 | |
| SCHEMBL5695804 | 0.83 | MEN1 (0.70) | MEN1KMT2AKDM4ESRD5A2FFAR1 | |
| SCHEMBL8726219 | 0.81 | MEN1 (0.68) | MEN1KMT2AKDM4ESRD5A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| CN-119162082-A | Method for preparing extrahepatic vesicles/apoptotic vesicles by inducing fibroblasts to be directly reprogrammed into liver-like cells and application of method | 中国人民解放军海军军医大学 | 2024-12-20 | — | — | CN | claimed |
| CN-118207152-A | Culture solution capable of promoting growth and improving functions of vascular endothelial stem cells | 张易 | 2024-06-18 | — | — | CN | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| CN-116904029-A | Preparation method of cross-linked sulfonated polyimide film | 西南科技大学 | 2023-10-20 | — | — | CN | claimed |
| US-11466252-B2 | Expansion and differentiation of inner ear supporting cells and methods of use thereof | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-10-11 | — | — | US | claimed |
| WO-2022182658-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| CN-111393695-B | Preparation method of self-crosslinking sulfonated polyimide membrane | 西南科技大学 | 2022-08-12 | — | — | CN | claimed |
| CN-114591249-A | Side chain type sulfonated aromatic diamine with ether bond and preparation method thereof | 中国石化扬子石油化工有限公司 | 2022-06-07 | — | — | CN | claimed |
| US-20200224159-A1 | UNIFIED CELL DIFFERENTIATION PROTOCOL | EYESTEM RESEARCH PRIVATE LIMITED (IN) | 2020-07-16 | — | — | US | claimed |
| WO-2019069327-A1 | UNIFIED CELL DIFFERENTIATION PROTOCOL | EYESTEM RESEARCH PRIVATE LIMITED (IN) | 2019-04-11 | — | — | WO | claimed |
| WO-2012050370-A2 | COMPOSITION FOR PREVENTING OR TREATING RHEUMATOID ARTHRITIS CONTAINING A GAMMA SECRETASE INHIBITOR AS AN ACTIVE INGREDIENT | 성균관대학교산학협력단 (KR) | 2012-04-19 | — | — | WO | claimed |
| US-20260103678-A1 | BILAYER OF RETINAL PIGMENTED EPITHELIUM AND PHOTORECEPTORS AND USE THEREOF | FUJIFILM Cellular Dynamics, Inc. (US) | 2026-04-16 | — | — | US | disclosed |
| EP-3458076-B1 | HUMAN AIRWAY STEM CELLS IN LUNG EPITHELIAL ENGINEERING | MASSACHUSETTS GEN HOSPITAL (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | KARUNA THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12492380-B2 | Methods for the production of hepatocytes | FUJIFILM Cellular Dynamics, Inc. (US) | 2025-12-09 | — | — | US | disclosed |
| US-6740371-B1 | EXCELLENT IN UNIFORMITY; DODECYL (3,5-BIS(4-AMINO BENZOYLAMINO)) BENZOATE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-05-25 | — | — | US | disclosed |
| US-6642347-B1 | Bismaleimide polymerization initiators; increasing toughness of thermosets | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE | 2003-11-04 | — | — | US | disclosed |
| EP-1209185-A1 | DIAMINOBENZENE DERIVATIVE, POLYIMIDE OBTAINED THEREFROM, AND LIQUID-CRYSTAL ALIGNMENT FILM | Nissan Chemical Industries, Ltd. (JP) | 2002-05-29 | — | — | EP | disclosed |
| US-5491200-A | FORMING GRAFT OR BLOCK COPOLYMER FROM POLYIMIDE ENDCAPPED WITH ACYL-ACTIVATED CAPROLACTAM RING AND MOLTEN CAPROLACTAM; FIBER BLENDS WITH NYLON-6; HEAT, CHEMICAL RESISTANT | EDISON POLYMER INNOVATION CORPORATION (US) | 1996-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | MEN1 2886/4885KMT2A 1550/4885KDM4E 2619/4885 |
| US-20260103678-A1 | BILAYER OF RETINAL PIGMENTED EPITHELIUM AND PHOTORECEPTORS AND USE THEREOF | PAX2, ZP1, ALDH1A2 | MEN1 1866/4885KMT2A 3593/4885KDM4E 3531/4885 |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | CHRM3, CHRM2, CHRM1 | MEN1 3715/4885KMT2A 4023/4885KDM4E 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.